FIVE PRIME THERAPEUTICS INC 4
4 · FIVE PRIME THERAPEUTICS INC · Filed Feb 9, 2017
Insider Transaction Report
Form 4
Baker Kevin Paul
SVP, Development Sciences
Transactions
- Award
Common Stock
2017-02-07+5,625→ 88,389 total - Award
Employee Stock Option (right to buy)
2017-02-07+25,000→ 25,000 totalExercise: $45.38Exp: 2027-02-06→ Common Stock (25,000 underlying) - Award
Common Stock
2017-02-07+7,031→ 95,420 total
Footnotes (4)
- [F1]Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 5, 2018, 2019 and 2020, provided the reporting person provides services to Five Prime Therapeutics, Inc. through each such date.
- [F2]Includes 264 shares of common stock granted to the reporting person by Five Prime Therapeutics, Inc. pursuant to a company match under Five Prime Therapeutics, Inc.'s 401(k) plan.
- [F3]Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on February 5, 2019 and two-thirds (2/3) of the restricted stock will vest on February 5, 2020, provided the reporting person provides services to Five Prime Therapeutics, Inc. through each such date.
- [F4]The shares underlying the option vest at a rate of one forty-eighth (1/48th) per month beginning on March 7, 2017, provided the reporting person provides services to Five Prime Therapeutics, Inc. through each such date.